{"success":true,"data":{"pressRelease":{"id":"45728","rtpr_id":"nGNXbRNZxV","ticker":"SYRE","exchange":"NASDAQ","all_tickers":["SYRE"],"title":"Spyre Therapeutics to Participate in Upcoming June Investor Conferences","author":"Globe Newswire","published_at":"2026-05-26T20:10:00.108Z","article_body":"WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc.\n(NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting\nantibodies and antibody combinations to redefine the standard of care for\ninflammatory bowel disease (“IBD”) and rheumatic diseases, today announced\nthat management will participate in the following upcoming investor\nconferences:\n\nEvent: Jefferies Global Healthcare Conference – New York\nDate: Wednesday, June 3, 2026\nFireside Time: 12:15 pm ET\n\nEvent: Goldman Sachs 47(th) Annual Global Healthcare Conference – Miami\nDate: Monday, June 8, 2026\nFireside Time: 10:00 am ET\n\nMembers of the Spyre management team will also host one-on-one investor\nmeetings during the conferences.\n\nLive audio webcasts and replays of these events will be available on the Spyre\ninvestor events website at https://ir.spyre.com/events-and-presentations.\n\nAbout Spyre Therapeutics\n\nSpyre Therapeutics is a clinical-stage biotechnology company pioneering\nlong-acting antibodies and antibody combinations to redefine the standard of\ncare for inflammatory bowel disease (“IBD”) and rheumatic diseases.\nSpyre's pipeline includes investigational extended half-life antibodies\ntargeting α4β7, TL1A, and IL-23.\n\nFor more information, visit Spyre's website at www.spyre.com. \n\nFor Investors:      \nEric McIntyre, Spyre Therapeutics\nSVP of Finance and Investor Relations\nEric.mcintyre@spyre.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bc26a912-b583-43c6-8423-55a4ba2bf4bd)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbRNZxV","title":"Spyre Therapeutics to Participate in Upcoming June Investor Conferences","author":"Globe Newswire","ticker":"SYRE","created":"2026-05-26T20:10:00.108Z","tickers":["SYRE"],"exchange":"NASDAQ","article_body":"WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc.\n(NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting\nantibodies and antibody combinations to redefine the standard of care for\ninflammatory bowel disease (“IBD”) and rheumatic diseases, today announced\nthat management will participate in the following upcoming investor\nconferences:\n\nEvent: Jefferies Global Healthcare Conference – New York\nDate: Wednesday, June 3, 2026\nFireside Time: 12:15 pm ET\n\nEvent: Goldman Sachs 47(th) Annual Global Healthcare Conference – Miami\nDate: Monday, June 8, 2026\nFireside Time: 10:00 am ET\n\nMembers of the Spyre management team will also host one-on-one investor\nmeetings during the conferences.\n\nLive audio webcasts and replays of these events will be available on the Spyre\ninvestor events website at https://ir.spyre.com/events-and-presentations.\n\nAbout Spyre Therapeutics\n\nSpyre Therapeutics is a clinical-stage biotechnology company pioneering\nlong-acting antibodies and antibody combinations to redefine the standard of\ncare for inflammatory bowel disease (“IBD”) and rheumatic diseases.\nSpyre's pipeline includes investigational extended half-life antibodies\ntargeting α4β7, TL1A, and IL-23.\n\nFor more information, visit Spyre's website at www.spyre.com. \n\nFor Investors:      \nEric McIntyre, Spyre Therapeutics\nSVP of Finance and Investor Relations\nEric.mcintyre@spyre.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bc26a912-b583-43c6-8423-55a4ba2bf4bd)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-26T20:10:00.141101731Z","server_sent_at_ms":1779826200141},"received_at":"2026-05-26T20:10:00.193Z","source_url":null},"analysis":{"id":"35160","press_release_id":"45728","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Spyre Therapeutics announced that management will participate in two upcoming investor conferences in early June.\n\nThe company will present at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8.\n\nOne-on-one investor meetings will also be hosted, with webcasts available on the company's investor relations website.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference schedule update -- no new catalysts disclosed."},"keyFigures":{},"quotedText":"Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences","namedEntities":{"people":[{"name":"Eric McIntyre","role":"SVP of Finance and Investor Relations"}],"products":[],"companies":[{"name":"Spyre Therapeutics, Inc.","ticker":"SYRE"},{"name":"Jefferies","relationship":"conference host"},{"name":"Goldman Sachs","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of participation in upcoming investor conferences. No new clinical data, partnership, or financial disclosure is included. This is standard corporate communications activity."},"tickerRelevance":{"others":[{"ticker":"JEF","relevance":"conference host"},{"ticker":"GS","relevance":"conference host"}],"primary":"SYRE"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_ir_activity","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Spyre Therapeutics announced that management will participate in two upcoming investor conferences in early June.\n\nThe company will present at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8.\n\nOne-on-one investor meetings will also be hosted, with webcasts available on the company's investor relations website.","key_figures":{},"named_entities":{"people":[{"name":"Eric McIntyre","role":"SVP of Finance and Investor Relations"}],"products":[],"companies":[{"name":"Spyre Therapeutics, Inc.","ticker":"SYRE"},{"name":"Jefferies","relationship":"conference host"},{"name":"Goldman Sachs","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-26T20:10:53.955Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_ir_activity","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":null,"modelName":"george-droid-qwen-72b"}}